12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25 –50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder

Treatment of severely symptomatic patients with generalized anxiety disorder (GAD) raises particular concerns for clinicians.This 12-week double-blind study evaluated the efficacy of agomelatine (25 –50 mg/day) in the treatment of patients with severe GAD, using escitalopram (10–20 mg) as active comparator. The primary outcome measure was the change from baseline of the total score on the Hamilton Anxiety scale (HAM-A) at week 12. Secondary outcome measures included rate of response to treatment (at least 50% score reduction from baseline) in the HAM-A psychic and somatic anxiety sub-scores, Clinical Global Impression severity and change scores, the Toronto Hospital Alertness Test, the Snaith-Hamilton Pleasure Scale, and the Leeds Sleep Evaluation Questionnaire Scores.

Source: European Neuropsychopharmacology - July 6, 2018 Category: Psychiatry & Psychology Authors: Dan J. Stein, Jon-Paul Khoo, Antti Ahokas, Marek Jarema, Michael. Van Ameringen, Livia Vavrusova, Cyril H ӧschl, Michael Bauer, Istvan Bitter, Sergey N. Mosolov, Valérie Olivier, Sophie Matharan, Françoise Picarel-Blanchot, Christian de Bodinat Source Type: research